ATS Medical Announces Fourth Quarter and Full Year 2009 Results
MINNEAPOLIS, March 1 /PRNewswire-FirstCall/ — ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today reported financial results for its fourth quarter and full year ended December 31, 2009.
Fourth Quarter Results
Revenue for the quarter was $18.7 million, or 3.7% higher, than the fourth quarter of 2008. On a constant currency basis, revenue growth for the fourth quarter was 2%. Without the effects of four more selling days in the fourth quarter of 2008, the impact of foreign currency translation and the discontinuance of the distribution of certain products in the third quarter of 2009, the Company’s adjusted revenue growth was 5.9%. A reconciliation of the GAAP revenue growth percentage to this non-GAAP adjusted revenue growth percentage for the fourth quarter of 2009 is provided in a schedule accompanying this press release.
Revenue from the Company’s heart valve therapy products, consisting of mechanical valves, tissue valves and heart valve repair products, was up 6.3% on a year-over-year basis in the fourth quarter to $13.9 million. Mechanical heart valve revenue decreased 3.4% on a year-over-year basis in the fourth quarter to $11.3 million. Tissue heart valve revenue for the fourth quarter increased 201% from the prior year’s quarter to $1.5 million. U.S. tissue heart valve revenue represented approximately 64% of the Company’s worldwide tissue heart valve revenue during the quarter. Heart valve repair revenue was $1.1 million, an increase of 29.5% over the fourth quarter of 2008.
Revenue from the Company’s ATS CryoMazeÃ‚® cryoablation products for the treatment of cardiac arrhythmias was $4.8 million, an increase of 2.6% compared to the $4.6 million in fourth quarter of 2008.
Gross profit margin for the fourth quarter of 2009 was 64.3% vs. 65.7% in the fourth quarter of 2008. The year-over-year gross margin decline is primarily the result of shifts in geographic and product mix.
Operating loss for the fourth quarter of 2009 was $2.8 million compared with an operating loss of $7.3 million in the fourth quarter of 2008. The GAAP net loss for the fourth quarter of 2009 was $3.5 million, or $0.05 per share, compared with $8.5 million, or $0.13 per share, in the fourth quarter of 2008. The operating and net losses for the fourth quarter of 2009 and 2008 included charges related to restructuring costs (2009) and legal settlement costs (2008) of $1.1 million and $7.5 million, respectively.
The Company also had a non-GAAP loss before interest, taxes, depreciation and amortization (EBITDA) in the fourth quarter of 2009 of $1.4 million compared to an EBITDA loss of $6.3 million in the fourth quarter of 2008. A reconciliation of reported net loss to non-GAAP EBITDA for these periods is provided in a schedule accompanying this press release. The Company ended the fourth quarter with $14.2 million in cash and cash equivalents and generated positive cash flow from operations during the quarter.
“While revenue growth from our mechanical heart valve and cryoablation products fell a bit below expectations in the fourth quarter as market growth rates slowed, we made significant progress on commercialization of the ATS 3fÃ‚® Aortic Bioprosthesis and the development of our new product pipeline, which we believe will enable us to return to double digit growth by the end of 2010,” said Michael Dale, President and Chief Executive Officer.
Full Year 2009 Results
Revenue for the full year 2009 increased 15.0% to $75.7 million compared to $65.8 million for 2008. On a constant currency basis revenue growth for 2009 was 17.1%. Heart valve therapy revenue grew 17.7% from $47.6 million in 2008 to $56.0 million in 2009 driven primarily by the expanded launch of the Company’s tissue valve products. Revenue from our CryoMaze cryoablation products increased 11.8% to $18.9 million in 2009.
Operating loss for 2009 was $3.7 million compared with an operating loss of $16.5 million for 2008. Net loss for 2009 was $6.3 million, or $0.09 per share, compared to $19.3 million, or $0.31 per share for 2008. Both the operating and net losses for 2009 and 2008 included non-recurring charges related to restructuring costs (2009) and legal settlement costs (2008) of $1.1 million and $7.5 million, respectively.
The Company had non-GAAP earnings before interest, taxes, depreciation and amortization (EBITDA) of $2.0 million for the full year 2009 compared to an EBITDA loss of $10.3 million for the full year 2008. A reconciliation of reported net loss to non-GAAP EBITDA for these periods is provided in a schedule accompanying this press release.
Recent Product Highlights and Upcoming Events
Mechanical Heart Valves
- The Company plans to begin human feasibility studies of its proprietary Forcefield technology applied to the OpenPivotÃ‚® mechanical heart valve in the second half of 2010. The Forcefield technology is designed to eliminate the need for chronic anticoagulant therapy with certain implantable devices through the use of electrical fields to modify the interaction between the blood and the device.
Tissue Heart Valves
- In December 2009, the Company received CE Mark of its ATS 3f Enable Bioprosthesis for commercialization in the European Union. The Enable valve combines the ATS 3f Aortic Bioprosthesis with over eight years of proven clinical performance and a self-expanding Nitinol(TM) frame to hold the valve in its optimal position eliminating the need for conventional sutures. This design allows the Enable valve to be folded into a small diameter and placed through a minimally invasive incision. Commercialization of the first generation Enable valve will be limited to a controlled market release at select surgical centers in Europe.
- The Company expects to begin commercialization of its second generation Enable valve in the second half of 2010. The second generation Enable will provide the basis for expansion of the Enable platform into a full market release.
- The Company is continuing to develop its sutureless tissue valve technology for use in beating heart procedures based in part on the characteristics of the next generation Enable valves. First-in-human clinical studies of this novel technology is targeted to occur during 2010. European commercialization of a beating heart solution could occur within one to two years thereafter.
Heart Valve Repair
- The Company expects to receive regulatory approval for an additional valve repair product in the second quarter of 2010. The additional product represents further expansion of the Company’s annuloplasty repair product portfolio to meet broader clinical applications.
- The Company has completed protocol development and will begin selecting investigation sites for the CryoMaze study, a prospective, multi-center clinical study of its CryoMaze cryoablation products to study the safety and efficacy of the use of the products for the treatment of atrial fibrillation. The study will have one year follow-up with interim data points to validate the safety and efficacy of the CryoMaze products used to create the lesions of the gold-standard Cox-Maze III lesion sets. This is the first and only multicenter study to mandate the Cox-Maze III lesion set for the treatment of atrial fibrillation with an energy source.
- The Company announced it will host an Analyst Day meeting in New York City on Monday, May 10, 2010, at which senior management and key opinion leading physicians will speak about the Company’s current and pipeline products. Specific details of the event will be provided in advance of the meeting and the meeting will be webcast.
- The Company also announced today it has received a commitment letter for term debt financing of approximately $30 million from one of its directors, Mr. Theodore C. Skokos, and The Ted and Shannon Skokos Foundation. This financing will be used to call and retire the Company’s convertible debt and senior bank debt instruments totaling approximately $26 million as well as to provide general corporate working capital. The Company expects to close the financing during the second quarter of 2010. When the convertible debt is retired the Company expects to recognize a non-cash debt restructuring charge of approximately $4.5 to $5.0 million related to the unamortized discount on the convertible debt.
“2010 will be an important year in many respects, perhaps most importantly because we will bring to market our first sutureless heart valve while also initiating our first human studies for both beating heart valve replacement and our Forcefield technology. Each of these solutions represents revolutionary initiatives that form the basis of our company’s aspiration to market leadership. Commercial success in our markets is all about “advancing the standards” of cardiac surgery and we are confident our current products and very importantly our pipeline portfolio meets and exceeds these measures,” commented Mr. Dale. “We look forward to sharing more details on our pipeline during our planned Analyst Day meeting in the second quarter.”
For the full year 2010 the Company expects revenue in the range of $81 to $83 million, representing growth of approximately 7% to 10%. The low-end of the revenue growth rate is approximately 1% less than preliminary guidance the Company provided in January due to recent volatility in the U.S. dollar to Euro exchange rate. Gross margin is expected to be within a range of 65% to 67% based on current expectations for product and geographic mix. Operating expenses are expected to be between $59 and $62 million as we invest in our sales and marketing infrastructure to support the U.S. and European roll-out of our Enable tissue valve and in research and development as we advance our robust product pipeline.
Conference Call Today
ATS management will host a conference call today, March 1, 2010, at 5:00 p.m. ET to discuss its 2009 fourth quarter financial results and current corporate developments. The dial-in number for the conference call is 866-314-4483 for domestic participants and 617-213-8049 for international participants with a passcode of 32431390. A live webcast of the call can also be accessed at www.atsmedical.com by clicking on the Investors icon.
A taped replay of the conference call will also be available beginning approximately one hour after the call’s conclusion and will remain available for seven days. The replay can be accessed by dialing 888-286-8010 for domestic participants and 617-801-6888 for international callers, using the passcode 61737878.
Disclosure of Non-GAAP Financial Measures
ATS reports its financial results in accordance with generally accepted accounting principles (“GAAP”). In addition, from time to time, we include other measures in our releases which are not prepared in accordance with GAAP. Investors should consider these non-GAAP financial measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. Non-GAAP financial measures used by ATS may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. In this release we have included disclosures of the adjusted percentage increase in revenue (adjusted revenue growth) for the fourth quarter of 2009 as well as earnings before interest, taxes, depreciation and amortization (EBITDA) , for the fourth quarter and full year periods of 2009 and 2008. Both of these disclosures are non-GAAP financial measures. We use both EBITDA and adjusted revenue growth rates in our internal analysis and review of our operational performance. We believe that these non-GAAP measures provide investors with useful information in comparing our operational performance over different periods. By using these non-GAAP measures we believe investors get a better picture of the performance of our underlying business. We have also included, as an attachment to this release, schedules which reconcile the percentage increase in revenue and the net loss reported in accordance with GAAP to the adjusted revenue growth percentage and EBITDA amounts presented above.
About ATS Medical
ATS Medical, Inc. is dedicated to ‘Advancing The Standards’ of cardiac surgery through the development, manufacturing and marketing of innovative products and services for the treatment of structural heart disease. ATS Medical serves the cardiac surgery community by focusing on two distinct but operationally synergistic market segments: heart valve disease therapy and surgical ablation of cardiac arrhythmias.
ATS was originally founded to develop the ATS Open PivotÃ‚® Heart Valve as a new mechanical heart valve standard of care. Today the ATS Open Pivot Heart Valve is the preferred mechanical heart valve in many markets around the world and the fastest growing mechanical prosthesis in the market. Building on this legacy and addressing the largest market segment in heart valve therapy, the ATS 3fÃ‚® brand encompasses an innovative tissue heart valve portfolio to address conventional open surgery requirements as well as the growing demand for less invasive sutureless based procedures. The ATS 3fÃ‚® portfolio includes offerings at various stages including early product development, pivotal clinical trials, and market commercialization. Completing the portfolio in heart valve therapy is the ATS SimulusÃ‚® annuloplasty product line. Simulus products assist the surgeon in repairing a patient’s native heart valve as an alternative to replacement. Continuing ATS Medical’s focus on serving the cardiac surgery community are the ATS CryoMazeÃ‚® products for surgical cryoablation of cardiac arrhythmias. ATS CryoMazeÃ‚® products are used by surgeons to treat patients suffering from cardiac arrhythmias, the largest and fastest growing form of structural heart disease in populations over 60 years of age. The ATS Medical web site is http://www.atsmedical.com.
This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the impact of pending healthcare reforms, regulatory actions, the terms of its outstanding debt obligations, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company’s activities and results, please refer to the Company’s filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2008 and its most recent quarterly report on Form 10-Q.
ATS Medical, Inc. Condensed Consolidated Statements of Operations (in thousands except per share amounts) --------------------------------------- (Unaudited) Quarter Ended Year Ended December 31, December 31, ------------ ------------ 2009 2008 2009 2008 ---- ---- ---- ---- Net sales $18,699 $18,032 $75,710 $65,821 Cost of goods sold 6,668 6,190 26,821 25,267 ----- ----- ------ ------ Gross profit 12,031 11,842 48,889 40,554 Operating expenses: Sales and marketing 8,641 6,680 30,617 27,373 Research and development 2,776 1,864 8,863 8,215 General and administrative 2,560 2,310 9,905 10,509 Litigation settlement - 7,500 - 7,500 Amortization of intangibles 812 817 3,224 3,489 --- --- ----- ----- Total operating expenses 14,789 19,171 52,609 57,086 ------ ------ ------ ------ Operating loss (2,758) (7,329) (3,720) (16,532) Interest expense, net (639) (763) (2,696) (2,739) Other income (expense), net (110) (224) 391 413 ---- ---- --- --- Net loss before income taxes (3,507) (8,316) (6,025) (18,858) Income tax (expense) benefit 26 (197) (288) (481) --- ---- ---- ---- Net loss ($3,481) ($8,513) ($6,313) ($19,339) ======= ======= ======= ======== Net loss per share: Basic and diluted ($0.05) ($0.13) ($0.09) ($0.31) ====== ====== ====== ====== Weighted average number of shares outstanding: Basic and diluted 73,629 63,580 72,114 61,440 ====== ====== ====== ======
ATS Medical, Inc. Condensed Consolidated Balance Sheets (in thousands) -------------- December 31, December 31, 2009 2008 ---- ---- Assets Cash and short-term investments $14,235 $20,895 Accounts receivable 14,398 14,532 Inventories, net 20,814 20,208 Prepaid expenses 1,774 958 ----- ----- Total current assets 51,221 56,593 Property and equipment, net 7,659 7,031 Intangible assets 61,076 49,131 Other assets 1,299 2,226 ----- ----- Total assets $121,255 $114,981 ======== ======== Liabilities & shareholders' equity Accounts payable $4,995 $4,054 Accrued compensation 2,076 3,537 Current maturities of bank notes payable 2,646 2,646 Convertible senior notes payable 17,659 - Payable to CryoCath Technologies Inc. 1,910 Payable to CarboMedics Inc. - 4,500 Other accrued liabilities 2,894 1,970 ----- ----- Total current liabilities 30,270 18,617 Convertible senior notes payable - 17,533 Bank notes payable 1,323 3,969 Other long-term liabilities 790 287 Shareholders' equity 88,872 74,575 ------ ------ Total liabilities & shareholders' equity $121,255 $114,981 ======== ========
ATS Medical, Inc. Consolidated Condensed Statements of Cash Flow (in thousands) -------------- Year Ended December 31, ----------------------- 2009 2008 ---- ---- Operating activities Net loss ($6,313) ($19,339) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 5,262 5,623 Stock-based compensation expense 2,557 1,676 Deferred income taxes 261 192 Non-cash interest expense 768 743 Change in value of warrant liability and derivative liability bifurcated from convertible senior notes (34) (294) Changes in operating assets and liabilities (5,357) (1,005) ------ ------ Net cash used in operating activities (2,856) (12,404) Investing activities Maturities of short-term investments, net of purchases - 4,189 Payments for business acquisitions (2,000) (2,000) Purchases of property and equipment (2,414) (1,440) Other 460 - --- --- Net cash provided by (used in) investing activities (3,954) 749 Financing activities Payments on notes payable (2,646) (1,985) Net proceeds from issuance of common stock 2,781 23,943 Other (20) 162 --- --- Net cash provided by financing activities 115 22,120 Effect of foreign exchange rate changes 35 (50) --- --- Increase (decrease) in cash and cash equivalents ($6,660) $10,415 ======= =======
ATS Medical, Inc. Selected Revenue Information (Unaudited, in thousands) ------------------------- Quarter Ended Year Ended December 31, December 31, ------------ ------------ 2009 2008 2009 2008 ---- ---- ---- ---- Heart valve therapy $13,871 $13,047 $56,015 $47,576 Surgical arrhythmia 4,764 4,643 18,881 16,888 Surgical tools & accessories 64 342 814 1,357 --- --- --- ----- Total revenue $18,699 $18,032 $75,710 $65,821 ======= ======= ======= =======
ATS Medical, Inc. Reconciliation of GAAP Revenue Growth Percentage to Non-GAAP Adjusted Revenue Growth Percentage (Unaudited) ----------- Quarter Ended December 31, 2009 ------------- GAAP revenue growth percentage, as reported 3.7% (Fourth quarter 2009 compared to fourth quarter 2008) Adjustments to GAAP revenue growth percentage for: Four more selling days in the fourth quarter of 2008 2.9% Impact of foreign currency translation (2.0%) Discontinuance of the distribution of certain products in the third quarter of 2009 1.3% --- Adjusted revenue growth percentage 5.9% ===
ATS Medical, Inc. Reconciliation of GAAP Net Loss to Non-GAAP EBITDA (Unaudited, in thousands) ------------------------- Quarter Ended Year Ended December 31, December 31, ------------ ------------ 2009 2008 2009 2008 ---- ---- ---- ---- Net loss, as reported $(3,481) $(8,513) $(6,313) $(19,339) Adjustments to net loss: Interest expense 642 772 2,723 2,923 Income tax expense (benefit) (26) 197 288 481 Depreciation 621 476 2,037 2,134 Amortization of intangibles 812 817 3,224 3,489 --- --- ----- ----- Earnings (loss) before interest, taxes, depreciation and amortization (EBITDA) $(1,432) $(6,251) $1,959 $(10,312) ======= ======= ====== ========
SOURCE ATS Medical, Inc.